Search results for "esca"

Investigazioni "sull'enigma" di una dedica

2007

Nella seconda metà del XIV secolo un francescano di Sciacca Andrea de Pace scrive il Viridarium principum e lo dedica a Nicola Peralta. Il saggio illustra le motivazioni della dedica ripercorrendo la vita del conte di Caltabellotta e i suoi rapporti con il francescano e con la monarchia.

El capitalismo, contra el planeta / 6

2007

Festival mediático

2007

Ascesa e catastrofe dell'uomo di fuoco. "L'amante schernito" di Girolamo Brusoni

2013

L’occupation du Néolithique final de Trémonteix (Puy-de-Dôme) et ses assemblages de mobilier

2020

In the heart of Auvergne (Puy-de-Dôme), the Late Neolithic settlement of Trémonteix is established beneath the Côtes de Clermont-Ferrand, a vast basalt plateau that dominates the north of the actual agglomeration. Within the framework of a rescue archaeology, an excavation conducted by Inrap, over 2588 m2 and has delivered several features and revealed a number of terraced constructions, dug into the bank of an ancient river bed. These are sheltered spaces (building 1) and artisanal activity zones, documented by pits and remains of occupation levels that were rich in finds. These constructions provided various pottery types, worked flint, an abundance of mainly domestic animal remains, work…

Argullol a vueltas con la opinión pública

2007

Immunophenotype based on inflammatory cells, PD-1/PD-L1 signalling pathway and M2 macrophages predicts survival in gastric cancer

2020

Abstract Background Immune response against cancer has prognostic impact but its role in gastric cancer is poorly known. The aim of the study was to assess the prognostic significance of immune cell score (CD3+, CD8+), tumour immune escape (PD-L1, PD-1) and immune tolerance (Clever-1). Methods After exclusion of Epstein-Barr virus positive (n = 4) and microsatellite instable (n = 6) tumours, the study included 122 patients with GC undergoing D2 gastrectomy. CD3+ and CD8+ based ICS, PD-L1, PD-1 and Clever-1 expressions were evaluated. Differences in survival were examined using Cox regression adjusted for confounders. The primary outcome was 5-year survival. Results The 5-year overall surviv…

The safety and efficacy of dasatinib plus nivolumab in patients with previously treated chronic myeloid leukemia: results from a phase 1b dose-escala…

2021

Although treatment with tyrosine kinase inhibitors (TKIs) has dramatically improved outcomes for the majority of patients with chronic myeloid leukemia (CML), approximately 20–30% will require a ch...

A phase I dose escalation and expansion study of the next generation oral SERD AZD9833 in women with ER-positive, HER2-negative advanced breast cancer

2020

1024 Background: AZD9833 is an oral selective estrogen receptor (ER) antagonist and degrader (SERD) that has shown antitumor efficacy in a range of preclinical models of breast cancer. Methods: SERENA-1 (NCT03616587) is an ongoing Phase 1, open-label study in pre- and post-menopausal women, after ≥1 endocrine therapy and ≤2 prior chemotherapies for ER+ HER2- advanced breast cancer (ABC). The primary objective is to determine the safety and tolerability of AZD9833 once daily (QD), with dose-limiting toxicities (DLTs) in 28d defining the maximum tolerated dose. Secondary objectives include pharmacokinetics and anti-tumor response. Pharmacodynamic (PD) analysis includes ER modulation in paire…

Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experi…

2014

10515 Background: Data from metastatic GIST patients harbouring exon 11 mutation who received a second line treatment with sunitinib or imatinib dose escalation were retrospectively analysed to compare survival. Methods: 123 exon 11 mutated advanced GIST patients were included. All patients progressed on imatinib 400 mg/die and received, on discretion of physician, a second line treatment with either imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 weeks of or 37.5 mg/day continuous daily dose). The type of exon 11 mutation was recorded (deletion versus others) and correlated with survival and response according to RECIST or CHOI criteria Results: 79 patients (64%) received a seco…